Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Next Previous
X
Search
Trial Profile

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Molgramostim (Primary) ; TG 01 Targovax (Primary) ; Dexamethasone
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Targovax

    • Most Recent Events

    • 09 Jul 2020 This trial is discontinued in Spain, according to European Clinical Trials Database record.
    • 17 Feb 2020 Results assessing the safety and efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma, published in the British Journal of Cancer
    • 23 May 2019 According to a Targovax ASA media release, this three-year survival data finalizes the data collection and the trial is now considered complete. The completed data will be presented and published later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top